We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PTC Therapeutics (PTCT) Soars: Stock Adds 9.4% in Session
Read MoreHide Full Article
PTC Therapeutics, Inc. (PTCT - Free Report) was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $31.72 to $37.47 in the past one-month time frame.
The stock gained after the company announced that it has inked a deal to acquire the biotechnology company, Agilis Biotherapeutics, Inc.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
PTC Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Is PTCT going up? Or down? Predict to see what others think:Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PTC Therapeutics (PTCT) Soars: Stock Adds 9.4% in Session
PTC Therapeutics, Inc. (PTCT - Free Report) was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $31.72 to $37.47 in the past one-month time frame.
The stock gained after the company announced that it has inked a deal to acquire the biotechnology company, Agilis Biotherapeutics, Inc.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
PTC Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
PTC Therapeutics, Inc. Price
PTC Therapeutics, Inc. Price | PTC Therapeutics, Inc. Quote
Investors interested in the Medical - Drugs industry may consider Taro Pharmaceutical Industries Ltd. , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is PTCT going up? Or down? Predict to see what others think:Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>